Quantum computing has been lurking in the background for years. Discover 5 cutting-edge science sectors like CRISPR and ...

CRISPR Therapeutics is still losing money, but it also finished March with $1.9 billion in cash after burning through $134 ...

The only gene-editing therapy currently on the market is a CRISPR–Cas9-based treatment for two blood disorders, sickle-cell ...

Researchers at UC Berkeley’s Innovative Genomics Institute, or IGI, developed a revolutionary treatment using CRISPR gene ...

A favorable appeals court ruling repositioned a coalition of universities and Nobel laureates to win credit for inventing a ...

On Wednesday, Clear Street analysts elevated CRISPR Therapeutics (NASDAQ:CRSP) stock rating from Hold to Buy, setting a new price ...

Vertex Pharmaceuticals has solid revenue projections for its CF franchise, and a promising drug pipeline, especially in pain.

Over the past decade, lipid nanoparticles (LNPs) have become a cornerstone in the field of nucleic acid delivery, with applications extending from vaccines ...

Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

Hillman Value Fund earns a High Process Pillar rating. The largest contributor to the rating is the firm's retention rate of the firm's portfolio managers, which is 100% over the timeframe for ...

© 2025 American City Business Journals. All rights reserved. Use of and/or registration on any portion of this site constitutes acceptance of our User Agreement ...